145733-36-4

基本信息
他沙索坦
2,4-二甲基-8-[[4-[2-(2H-四唑-5-基)苯基]苯基]甲基]-5,6-二氫吡啶并[6,5-D]嘧啶-7-酮
CS-160
DB01349
ANA-756
AC1Q6LAA
AC1L1U5X
Tasosarta
TASOSARTAN
WAY-ANA-756
S1539_Selleck
物理化學(xué)性質(zhì)
制備方法
![Pyrido[2,3-d]pyrimidin-7(6H)-one, 8-[[2'-[1-(1,1-dimethylethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-5,8-dihydro-2,4-dimethyl-](/CAS/20210305/GIF/149049-80-9.gif)
149049-80-9

145733-36-4
步驟6)將2,4-二甲基-5,6,8-三氫-8-[[2'-(1H-四唑-5-基)[1,1'-聯(lián)苯]-4-基]甲基]-7H-吡啶并[2,3-d]嘧啶-7-酮與2,4-二甲基-5,6,8-三氫-8-[[2'-(1-叔丁基-1H-四唑-5-基)[1,1'-聯(lián)苯]-4-基]甲基]-7H-吡啶并[2,3-d]嘧啶-7-酮的混合物(200 mg,0.428 mmol)溶于甲苯(4 mL)中,加入甲磺酸(280 mL,4.28 mmol),加熱回流18小時(shí)。反應(yīng)完成后,將混合物濃縮,加入水(2 mL)和1N KOH溶液(4.5 mL)調(diào)節(jié)至pH 8。用乙酸乙酯(EtOAc)萃取混合物以除去未反應(yīng)的原料,隨后將水相用1N HCl酸化至pH 5,得到膠狀沉淀物。將沉淀物溶于乙酸乙酯中,溶液經(jīng)無水硫酸鎂(MgSO4)干燥后濃縮,得到無色油狀物。用丙酮/乙醚混合溶劑研磨,得到70 mg(40%產(chǎn)率)目標(biāo)產(chǎn)物,為白色固體,熔點(diǎn)為197°C-198°C。1H NMR(DMSO-d6)δ: 2.35(s,3H),2.42(s,3H),2.72(t,J = 7.2 Hz,2H),2.87(t,J = 7.2 Hz,2H),5.17(s,2H),6.99(d,J = 8.2 Hz,2H),7.18(d,J = 8.2 Hz,2H),7.54(m,2H),7.65(m,2H)。IR(KBr,cm-1): 1710(C=O)。
參考文獻(xiàn):
[1] Patent: US5256654, 1993, A
[2] Patent: US5149699, 1992, A
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2025/05/22 | HY-A0250 | 他索沙坦 Tasosartan | 145733-36-4 | 1 mg | 600元 |
2025/05/22 | HY-A0250 | 他索沙坦 Tasosartan | 145733-36-4 | 5mg | 1500元 |
2025/05/22 | HY-A0250 | 他索沙坦 Tasosartan | 145733-36-4 | 10mg | 2400元 |
常見問題列表
Angiotensin II (AngII) receptor
Tasosartan is an orally active nonpeptide AngII antagonist that has demonstrates specific and selective AT1 receptor antagonistic activity in vitro. IC 50 for inhibition of specific binding of 125 I-AngII to rat adrenal membrane in the absence of proteins in binding buffer is 1.2±0.6 nM.
Administration of Tasosartan at doses of 1.0 and 3.0 mg/kg (iv) significantly (p<0.05) attenuates the pressor response to angiotensin-II in rats.